Message from the Guest Editor

Dear Colleagues,

The progress in gene therapy has been hampered by delivery inefficacy and safety concerns. Recent progress has casted some promising light on future development. A number of viral vectors have been re-engineered for improved delivery and enhanced safety. In this context, adenovirus, adeno-associated virus, lentivirus, retroviruses and other virus vectors have provided therapeutic efficacy for various diseases such as severe combined immunodeficiency, hemophilia, cancer and infectious diseases. The discovery of RNA interference, particularly the use of short interfering RNA and micro-RNA for reversible gene silencing, has substantially widened the application range of gene therapy. In this Special Issue, applications of various viral vectors and their use in gene therapy are reviewed with a special emphasis on RNA interference.

Dr. Kenneth Lundstrom
Guest Editor

Author Benefits

Open Access: free for readers, with publishing fees paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science), MEDLINE (PubMed) and other databases. Full-text available in PubMed Central.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 33 days after submission; acceptance to publication is undertaken in 8 days (median values for papers published in this journal in 2016).

Editorial Section highlighting important developments to a broad audience of virologists and written by leading experts in the field.